Related Experiment Video
Updated: Jul 11, 2026
19:57
An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
Published on: March 30, 2014
Patient preferences among third agent HIV medications: a US and German perspective
K M Beusterien1, K Dziekan, S Schrader
1Oxford Outcomes, Bethesda, MD 20814, USA. Kathy.beusterien@oxfordoutcomes.com
AIDS Care
|September 14, 2007
Summary
Patient preferences for third-agent HIV medications reveal that developing drug resistance, side effects, and convenience are key. Fosamprenavir/ritonavir (FPVr) was the most preferred regimen among participants in this study.
Area of Science:
- Pharmacoeconomics
- HIV/AIDS Therapeutics
- Patient-Reported Outcomes
Background:
- Third-agent HIV medications are crucial for treatment-experienced and treatment-naïve patients.
- Understanding patient preferences is vital for optimizing HIV treatment regimens.
- Several third-agent options exist, each with distinct attribute profiles.
Purpose of the Study:
- To assess patient preferences for attributes of third-agent HIV medications.
- To determine the relative importance of medication attributes in HIV treatment decisions.
- To identify the most preferred third-agent HIV medication profile based on patient-valued attributes.
Main Methods:
- A computerized adaptive conjoint survey was administered to 288 HIV-positive participants in the US and Germany.
- The survey assessed preferences for 13 attributes, including side effects, convenience, drug resistance, and efficacy.
- Preference weights were calculated to estimate attribute importance and medication desirability.
Main Results:
- Developing drug resistance, lipodystrophy risk, gastrointestinal side effects, and regimen convenience significantly impacted patient preferences.
- The medication profile based on fosamprenavir/ritonavir (FPVr) was the most preferred among participants.
- Attribute differences in drug resistance, lipodystrophy, GI side effects, and convenience most influenced perceived medication value.
Conclusions:
- Patient preferences for third-agent HIV medications are driven by risks of drug resistance, specific side effects, and convenience.
- Fosamprenavir/ritonavir (FPVr) emerged as the most preferred option in this study.
- Physicians should consider these key attributes when discussing HIV treatment options with patients to enhance adherence and outcomes.
Related Concept Videos
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
01:13Bioequivalence studies: Biowaivers
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:29Factors Affecting Protein-Drug Binding: Patient-Related Factors
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...